Diagnosis of endocrine disease: limitations of the IGF1 generation test in children with short stature
| Autor: | Régis Coutant, Helmuth-Günther Dörr, Jesús Argente, Helena Gleeson |
|---|---|
| Přispěvatelé: | Biologie Neurovasculaire Intégrée (BNVI), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism media_common.quotation_subject [SDV]Life Sciences [q-bio] MEDLINE Body Height/physiology 030209 endocrinology & metabolism Short stature Severity of Illness Index 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin-Like Growth Factor I/biosynthesis/physiology Predictive Value of Tests Internal medicine Severity of illness medicine Humans Growth Disorders/blood/diagnosis/physiopathology Laron Syndrome/blood/diagnosis/physiopathology Insulin-Like Growth Factor I Child Normality Growth Disorders 030304 developmental biology media_common 0303 health sciences Endocrine disease business.industry General Medicine medicine.disease Body Height Laron Syndrome 3. Good health Test (assessment) Predictive value of tests Growth Hormone Growth Hormone/blood/physiology Abnormality medicine.symptom business |
| Zdroj: | European Journal of Endocrinology European Journal of Endocrinology, 2011, 166 (3), pp.351-7. ⟨10.1530/EJE-11-0618⟩ |
| ISSN: | 1479-683X |
| DOI: | 10.1530/EJE-11-0618⟩ |
| Popis: | The IGF1 generation test (IGFGT) is often used during the assessment of suspected GH insensitivity (GHI). We report the results of a survey undertaken in 2010 to determine the use of IGFGT amongst members of the European Society for Paediatric Endocrinology to evaluate suspected GHI. The literature surrounding the usefulness and limitations of IGFGT are reviewed, and recommendations provided for its use. Of 112 paediatric endocrinologists from 30 countries who responded to the survey, 91 (81%) reported that they had used the IGFGT in the previous 2 years; >10 IGFGT protocols were used. The IGFGT impacted treatment decisions for 97% of the respondents and was a prerequisite for recombinant human IGF1 treatment for 45% of respondents. From a literature review, sensitivity of the IGFGT was evaluated as 77–91% in molecularly proven cases of GHI; specificity was ≤97%, depending on the protocol. The positive predictive value of the IGFGT is likely to be low, as the frequency of normality is predictably higher than that of abnormality in GH signalling. Given the limitations of the IGFGT in the most severe cases of GHI syndrome (GHIS), the ability of the IGFGT to detect less severe GHIS is doubtful. In a pragmatic approach, the IGFGT may not be useful for the diagnosis of GHIS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|